Literature DB >> 23293702

Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options.

Prajnan Das1, Vivian E Strong, Jaffer A Ajani.   

Abstract

Entities:  

Year:  2012        PMID： 23293702      PMCID： PMC3533849     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  8 in total

1.  Preoperative chemoradiotherapy for esophageal or junctional cancer.

Authors:  P van Hagen; M C C M Hulshof; J J B van Lanschot; E W Steyerberg; M I van Berge Henegouwen; B P L Wijnhoven; D J Richel; G A P Nieuwenhuijzen; G A P Hospers; J J Bonenkamp; M A Cuesta; R J B Blaisse; O R C Busch; F J W ten Kate; G-J Creemers; C J A Punt; J T M Plukker; H M W Verheul; E J Spillenaar Bilgen; H van Dekken; M J C van der Sangen; T Rozema; K Biermann; J C Beukema; A H M Piet; C M van Rij; J G Reinders; H W Tilanus; A van der Gaast
Journal:  N Engl J Med       Date:  2012-05-31       Impact factor: 91.245

2.  Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS).

Authors:  Johan L Dikken; Johanna W van Sandick; H A Maurits Swellengrebel; Pehr A Lind; Hein Putter; Edwin P M Jansen; Henk Boot; Nicole C T van Grieken; Cornelis J H van de Velde; Marcel Verheij; Annemieke Cats
Journal:  BMC Cancer       Date:  2011-08-02       Impact factor: 4.430

3.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.

Authors:  Mitsuru Sasako; Shinichi Sakuramoto; Hitoshi Katai; Taira Kinoshita; Hiroshi Furukawa; Toshiharu Yamaguchi; Atsushi Nashimoto; Masashi Fujii; Toshifusa Nakajima; Yasuo Ohashi
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

4.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.

Authors:  Jeeyun Lee; Do Hoon Lim; Sung Kim; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Min Gew Choi; Tae Sung Sohn; Jae Hyung Noh; Jae Moon Bae; Yong Chan Ahn; Insuk Sohn; Sin Ho Jung; Cheol Keun Park; Kyoung-Mee Kim; Won Ki Kang
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

5.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.

Authors:  J S Macdonald; S R Smalley; J Benedetti; S A Hundahl; N C Estes; G N Stemmermann; D G Haller; J A Ajani; L L Gunderson; J M Jessup; J A Martenson
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

6.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Young-Woo Kim; Han-Kwang Yang; Hyun Cheol Chung; Young-Kyu Park; Kyung Hee Lee; Keun-Wook Lee; Yong Ho Kim; Sang-Ik Noh; Jae Yong Cho; Young Jae Mok; Yeul Hong Kim; Jiafu Ji; Ta-Sen Yeh; Peter Button; Florin Sirzén; Sung Hoon Noh
Journal:  Lancet       Date:  2012-01-07       Impact factor: 79.321

7.  Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.

Authors:  Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

8.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.

Authors:  David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H Van de Velde; Marianne Nicolson; J Howard Scarffe; Fiona J Lofts; Stephen J Falk; Timothy J Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Journal:  N Engl J Med       Date:  2006-07-06       Impact factor: 91.245
  8 in total
  1 in total

1.  CagA orchestrates eEF1A1 and PKCδ to induce interleukin-6 expression in Helicobacter pylori-infected gastric epithelial cells.

Authors:  Shaohan Xu; Xiaoqian Wu; Xiaoyan Zhang; Chu Chen; Hao Chen; Feifei She
Journal:  Gut Pathog       Date:  2020-07-03       Impact factor: 4.181
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.